Research Infrastructure Monitoring and Competence Evaluation Committee visited IBG (Izmir Biomedicine and Genome Center)

Research Infrastructure Monitoring and Competence Evaluation Committee visited IBG (Izmir Biomedicine and Genome Center)

Research Infrastructure Monitoring and Competence Evaluation Committee visited IBG (Izmir Biomedicine and Genome Center)

Research Infrastructure Monitoring and Competence Evaluation Committee Members Deputy Minister of Industry and Technology and Committee Chairman Mehmet Fatih Kacır, Deputy President of the Council of Higher Education. Dr. M. İ. Safa Kapıcıoğlu, President of TÜBİTAK Prof. Dr. Hasan Mandal, TÜBİTAK ARGES Director Dr. Dilek Candan, TUBITAK ARGES Experts Seda Şirin and Tuğçe Başer, DEU Vice Rector. Prof. Dr. Uğur Malayoğlu, DEU Secretary General Dr. Saip Tiryakioğlu, IBG Board of Directors Members Prof. Dr. Mehmet Volkan Atalay, Msc. Pharm. M. Vedat Eğilmez, CEO of ESBAS (Aegean Free Zone Dev. & Oper. Comp.) Dr. Faruk Güler, Prof. Dr. Murat Özgören and Director of IBG & Director of Technological Reserach Program Prof. Dr. Mehmet Öztürk, IBG Board of Directors Candidate Members Prof. Dr. Figen Coşkun, Prof. Dr. Mehmet Erduran and Prof. Dr. Mehmet Birhan Yılmaz, IBG Asistant Directors Dr. Soner Gündemir, Asuman Öcal and Melih Aydemir, İBG Director of Basic and Translational Research Program Prof. Dr. Stefan Dimitrov, Asst. Director of Basic and Translational Research Program Prof. Dr. Neşe Atabey and Asst. Director of IBG Technogical Reserach Program Prof. Dr. Mehmet İnan and IBG Researchers. Information about the vision of the Basic and Translational Research and Technological Research Programs in related areas, the projects realized in 2019, the 2020 targets and especially the national and international projects in the field of cancer & rare diseases and drug development were provided. Later, some of the Strategic Products of IBG such as innovative endoscopy apparatus, biosimilar drug for cancer and osteoporosis, superior bio-drug for eye diseases, Kar-T cellular therapy drugs and PROT-ON: in silico drug design software were presented. Within the scope of the needs and research priorities in our country, national and international joint projects and strategic alliances that may be formed between DEU and IBG were evaluated in the meeting. With the visit of IBG research and innovation laboratories the meeting ended.